# Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

> **NCT06265285** · PHASE2 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 50 (estimated)

## Conditions studied

- Advanced Esophageal Squamous Cell Carcinoma
- Advanced Renal Cell Carcinoma
- Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8
- Clinical Stage IIB Cutaneous Melanoma AJCC v8
- Clinical Stage IIC Cutaneous Melanoma AJCC v8
- Clinical Stage III Cutaneous Melanoma AJCC v8
- Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8
- Esophageal Carcinoma
- Gastroesophageal Junction Adenocarcinoma
- Hepatocellular Carcinoma
- Locally Advanced Urothelial Carcinoma
- Lung Non-Small Cell Carcinoma
- Malignant Solid Neoplasm
- Metastatic Colorectal Carcinoma
- Metastatic Cutaneous Melanoma
- Metastatic Esophageal Squamous Cell Carcinoma
- Metastatic Head and Neck Squamous Cell Carcinoma
- Metastatic Urothelial Carcinoma
- Recurrent Esophageal Squamous Cell Carcinoma
- Recurrent Head and Neck Squamous Cell Carcinoma
- Renal Cell Carcinoma
- Stage III Renal Cell Cancer AJCC v8
- Stage IV Colorectal Cancer AJCC v8
- Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
- Stage IV Renal Cell Cancer AJCC v8
- Unresectable Cutaneous Melanoma
- Unresectable Esophageal Squamous Cell Carcinoma
- Urothelial Carcinoma
- Unresectable Urothelial Carcinoma

## Interventions

- **OTHER:** Home Health Encounter
- **BIOLOGICAL:** Nivolumab
- **PROCEDURE:** Patient Monitoring
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT06265285
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-30
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06265285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06265285, "Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program". Retrieved via AI Analytics 2026-05-19 from https://api.ai-analytics.org/clinical/NCT06265285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*